The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg aims to understand a patient’s individual condition, establish appropriate diagnostics, advance prevention and optimize therapies.
Our focus is on new inhalation technologies and on novel technologies for administration of therapeutic aerosols by smart drug/device combination products.
Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.
The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.
Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.
RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.
Our Annual Report allows you to get an insight into our research activities and objectives, but also into the way we work and the people behind all this.
Our Annual Report each year gives an account of the work done in our different business areas and of selected research results.
If you prefer to read a printed version of our Annual Report, please subscribe to the printed version. We will be pleased to send you a copy and hope you will enjoy reading it.
A chapter in our Annual Report documents the "Names, dates and facts" for this particular year. For up-to-date informationen in the individual subject areas, please click below on the corresponding link:
Fraunhofer Institute for Toxicology and Experimental Medicine